Please ensure Javascript is enabled for purposes of website accessibility

Boston Scientific Evaluates New Pacing System

By Rich Duprey - Apr 15, 2013 at 10:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Medical device maker will study compatibility with MRIs

In an effort to give patients with pacemakers fuller access to sophisticated diagnostic equipment, Boston Scientific (BSX -0.05%) will evaluate whether it's safe to give patients with its new pacing system MRI scans.

According to the company, most pacemakers are not compatible with magnetic resonance imaging systems because MRIs create interference with the performance of pacing systems, which are designed to treat bradycardia, a condition in which the heart beats too slowly and deprives the body of sufficient oxygen. Thus patients end up being unable to access the technology's full scanning capabilities.

As a result, Boston Scientific says it will test its next-generation ImageReady MR Conditional pacing system in the SAMURAI clinical trial, which is designed to confirm the safety and effectiveness of the system in an MRI environment.

The ImageReady pacing system is under clinical investigation and not currently available for sale in the United States. The SAMURAI trial is a two-group randomized global clinical study designed to support FDA regulatory approval and is expected to enroll approximately 363 patients at 45 centers in seven countries. 

link

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Boston Scientific Corporation Stock Quote
Boston Scientific Corporation
BSX
$40.07 (-0.05%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.